What is a safe medication for treating restless‑leg syndrome in a patient with acute kidney injury?

Safe Medication for Restless Leg Syndrome in Acute Kidney Injury

For a patient with acute kidney injury (AKI) and restless leg syndrome, gabapentin is the safest and most appropriate medication choice, with dose adjustment required for renal function. While the 2025 AASM guidelines provide strong recommendations for gabapentin, gabapentin enacarbil, and pregabalin in general RLS populations, these alpha-2-delta ligands require careful dosing in renal impairment 1.

Primary Recommendation: Gabapentin with Renal Dose Adjustment

Gabapentin receives a strong recommendation from the 2025 AASM guidelines for RLS treatment 1. Critically, gabapentin is also specifically recommended for patients with end-stage renal disease (ESRD), demonstrating its safety profile across the spectrum of kidney dysfunction 1. This makes it the logical choice for AKI patients, bridging the gap between normal renal function and ESRD.

Dosing Considerations in AKI:

• Standard RLS dose: 200-300 mg in dialysis patients 2
• Adjust based on creatinine clearance: Lower doses and extended intervals are essential
• Monitor for accumulation: Gabapentin is renally cleared; sedation and dizziness indicate toxicity
• Start low, go slow: Begin with 100-200 mg post-dialysis if on dialysis, or once daily if not

Evidence Supporting Gabapentin in Kidney Disease:

Multiple studies demonstrate gabapentin's efficacy specifically in renal populations. In hemodialysis patients, gabapentin produced significant IRLS score reductions of approximately 17 points compared to 13 points with levodopa 2. A 2022 network meta-analysis confirmed gabapentin as the most effective pharmacological intervention for ESKD patients with RLS, also improving sleep quality 3. A 2026 systematic review reinforced that gabapentinoids produce the largest symptom reductions in hemodialysis patients 4.

Alternative Options (Listed by Safety in AKI)

Iron Supplementation (First-Line if Iron Deficient)

Check iron parameters immediately - ferritin and transferrin saturation are essential before any pharmacotherapy 1.

• IV iron sucrose: Specifically recommended for RLS in ESRD patients with ferritin <200 ng/mL and transferrin saturation <20% 1
• Safe in AKI: Iron metabolism is not significantly altered by acute renal dysfunction
• Moderate efficacy: Conditional recommendation with moderate certainty of evidence 1
• Minimal adverse effects: Well-tolerated in renal populations

Vitamin C

• Conditional recommendation for ESRD patients with RLS 1
• Extremely safe in AKI: Water-soluble, minimal toxicity
• Low certainty evidence: Limited data but favorable safety profile
• Consider as adjunct: May enhance iron absorption and utilization

Medications to AVOID in AKI

Pregabalin

While pregabalin receives a strong recommendation for general RLS 1, it requires more aggressive dose reduction than gabapentin in renal impairment and has higher risk of accumulation. Use gabapentin instead.

Dopamine Agonists (Pramipexole, Ropinirole, Rotigotine)

• Suggested AGAINST for standard use even in normal renal function 1
• Augmentation risk: Long-term use causes worsening symptoms
• Renal excretion concerns: Pramipexole particularly problematic in renal dysfunction
• Avoid entirely in AKI

Opioids

• Conditional recommendation in general population 1
• Dangerous in AKI: Accumulation of active metabolites, respiratory depression risk
• Reserve for refractory cases only after AKI resolution

Levodopa

• Suggested against for standard use due to augmentation and rebound 1
• Short duration of action: Impractical for sustained symptom control
• Not appropriate for AKI patients

Benzodiazepines and Anticonvulsants

• Clonazepam, valproic acid, carbamazepine: All receive recommendations AGAINST use 1
• Increased toxicity in AKI: Altered protein binding and clearance

Clinical Algorithm for AKI Patients with RLS

1. Assess iron status immediately: Ferritin and transferrin saturation

   • If ferritin <200 ng/mL and TSAT <20%: Give IV iron sucrose
   • Continue to step 2 if symptoms persist

2. Estimate renal function: Calculate CrCl or use eGFR

   • Start gabapentin 100-200 mg once daily (adjust based on CrCl)
   • If on dialysis: Give post-dialysis session

3. Monitor response at 1-2 weeks:

   • Assess symptom improvement and adverse effects
   • Titrate dose cautiously if inadequate response
   • Watch for sedation, dizziness, peripheral edema

4. Add vitamin C if suboptimal response (500-1000 mg)

Critical Pitfalls to Avoid

• Do NOT use standard RLS doses: Renal dosing is mandatory
• Do NOT start dopamine agonists: Even if previously effective, augmentation risk outweighs benefits
• Do NOT overlook iron deficiency: This is correctable and may resolve RLS entirely
• Do NOT use pregabalin as first choice: Gabapentin has better safety data in renal disease
• Do NOT forget drug accumulation: AKI is dynamic; what's safe today may be toxic tomorrow as renal function changes

The evidence strongly supports gabapentin as the safest pharmacological choice, with iron supplementation addressing the underlying pathophysiology when deficiency is present 1, 4, 3, 2.